Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study

Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study

Background: Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness in reducing the risk of hospitalization and mortality in comparison to warfarin among nonvalvular AF patients in Saud...

Full description

Bibliographic Details
Main Authors: Yazed AlRuthia, Bushra Q. AlOtaibi, Reem M. AlOtaibi, Najla Q. AlOtaibi, Miteb Alanazi, Ghadah Asaad Assiri
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Saudi Pharmaceutical Journal
Subjects:
Anticoagulation
Cost effectiveness
Atrial fibrillation
Rivaroxaban
Warfarin
Online Access:http://www.sciencedirect.com/science/article/pii/S1319016422002791

Internet

http://www.sciencedirect.com/science/article/pii/S1319016422002791

Similar Items